Phio Pharmaceuticals Corp - Understand $phio stock

$PHIO Market Cap: $1.919 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$7.419M

TTM

Current Assets

$5.864M

Q3 2024

Current Liabilities

$919.0K

Q3 2024

Current Ratio

638.08%

Q3 2024

Total Assets

$5.865M

Q3 2024

Total Liabilities

Book Value

Cash

$5.390M

Q3 2024

P/E

-0.2587

Nov 14, 2024 EST

Free Cash Flow

-$4.147M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$0.00	$0.00	$0.00	$0.00	$20.00K	$140.0K	$15.00K	$19.00K	$34.00K	$71.00K	$399.0K	$97.00K	$0.00	$0.00
YoY Change				-100.0%	-85.71%	833.33%	-21.05%	-44.12%	-52.11%	-82.21%	311.34%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	$0.00	$0.00	$0.00	$0.00	$20.00K	$140.0K	$15.00K	$19.00K	$34.00K	$71.00K	$399.0K	$97.00K	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Selling, General & Admin	$4.366M	$4.450M	$4.625M	$4.360M	$4.710M	$3.180M	$4.010M	$3.620M	$3.350M	$3.220M	$3.700M	$2.620M	$6.150M	$8.750M
YoY Change	-1.89%	-3.78%	6.08%	-7.43%	48.11%	-20.7%	10.77%	8.06%	4.04%	-12.97%	41.22%	-57.4%	-29.71%
% of Gross Profit
Research & Development	$6.332M	$7.012M	$8.886M	$4.430M	$4.300M	$4.330M	$5.370M	$5.415M	$6.925M	$5.680M	$17.65M	$10.45M	$6.624M	$7.870M
YoY Change	-9.7%	-21.09%	100.59%	3.02%	-0.69%	-19.37%	-0.83%	-21.81%	21.92%	-67.82%	68.89%	57.77%	-15.83%
% of Gross Profit
Depreciation & Amortization	$56.00K	$71.00K	$75.00K	$70.00K	$70.00K	$80.00K	$70.00K	$53.00K	$77.00K	$87.00K	$99.00K	$147.0K	$160.0K	$170.0K
YoY Change	-21.13%	-5.33%	7.14%	0.0%	-12.5%	14.29%	32.08%	-31.17%	-11.49%	-12.12%	-32.65%	-8.13%	-5.88%
% of Gross Profit
Operating Expenses	$10.70M	$11.46M	$13.51M	$8.790M	$9.010M	$7.500M	$14.08M	$9.034M	$10.27M	$8.897M	$21.35M	$13.07M	$6.624M	$16.63M
YoY Change	-6.67%	-15.17%	53.71%	-2.44%	20.13%	-46.72%	55.82%	-12.04%	15.44%	-58.32%	63.31%	97.34%	-60.17%
Operating Profit	-$10.82M	-$11.46M	-$13.51M				-$14.06M	-$9.015M	-$10.24M	-$8.826M	-$20.95M	-$12.98M	-$12.77M
YoY Change	-5.57%	-15.17%					55.98%	-11.94%	15.99%	-57.87%	61.46%	1.61%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Interest Expense			-$9.000K				-$1.000K	$15.00K	$16.00K	$17.00K	$24.00K	-$30.00K	$0.00	$10.00K
YoY Change							-106.67%	-6.25%	-5.88%	-29.17%	-180.0%		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$2.000K	-$18.00K	$224.0K	$0.00	$80.00K	$0.00	-$11.00K	$21.00K	$14.00K	$26.00K	$0.00	$125.0K	$2.551M	$4.630M
YoY Change	-88.89%	-108.04%		-100.0%		-100.0%	-152.38%	50.0%	-46.15%		-100.0%	-95.1%	-44.9%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Pretax Income	-$10.83M	-$11.48M	-$13.29M	-$8.790M	-$8.910M	-$7.360M	-$14.07M	-$8.994M	-$10.22M	-$8.800M	-$20.93M	-$12.88M	-$10.22M	-$11.99M
YoY Change	-5.7%	-13.6%	51.16%	-1.35%	21.06%	-47.7%	56.47%	-12.02%	16.17%	-57.95%	62.46%	26.04%	-14.77%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	-$1.621M	$0.00	$0.00	$0.00	$0.00			$0.00
% Of Pretax Income
Net Earnings	-$10.83M	-$11.48M	-$13.29M	-$8.790M	-$8.910M	-$7.360M	-$12.45M	-$8.994M	-$10.22M	-$8.800M	-$20.93M	-$12.88M	-$2.537M	-$11.99M
YoY Change	-5.7%	-13.6%	51.16%	-1.35%	21.06%	-40.89%	38.45%	-12.02%	16.17%	-57.95%	62.46%	407.69%	-78.85%	-34.77%
Net Earnings / Revenue					-44550.0%	-5257.14%	-83013.33%	-47336.84%	-30067.65%	-12394.37%	-5244.36%	-13278.35%
Basic Earnings Per Share	-$5.20	-$10.10	-$12.43
Diluted Earnings Per Share	-$5.20	-$10.10	-$1.036M	-$1.915M	-$19.37M	-$56.62M	-$311.3M	-$899.0M	-$1.022B	-$4.347B	-$15.83B	-$30.90B	-$46.42B	-$111.0B

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Cash & Short-Term Investments	$8.490M	$11.78M	$24.06M	$14.24M	$6.930M	$14.88M	$3.580M	$12.91M	$10.62M	$8.500M	$14.39M	$5.130M	$500.0K	$6.890M
YoY Change	-27.93%	-51.03%	68.94%	105.48%	-53.43%	315.64%	-72.27%	21.56%	24.94%	-40.93%	180.51%	926.0%	-92.74%
Cash & Equivalents	$8.490M	$11.78M	$24.06M	$14.24M	$6.930M	$14.88M	$3.580M	$12.91M	$5.120M	$8.500M	$11.39M	$5.130M	$500.0K	$6.890M
Short-Term Investments									$5.500M	$0.00	$3.000M
Other Short-Term Assets	$832.0K	$665.0K	$670.0K	$920.0K	$370.0K	$270.0K	$250.0K	$200.0K	$360.0K	$490.0K	$350.0K	$260.0K	$240.0K	$150.0K
YoY Change	25.11%	-0.75%	-27.17%	148.65%	37.04%	8.0%	25.0%	-44.44%	-26.53%	40.0%	34.62%	8.33%	60.0%
Inventory
Prepaid Expenses
Receivables												$0.00	$600.0K	$0.00
Other Receivables												$0.00	$0.00	$0.00
Total Short-Term Assets	$9.322M	$12.45M	$24.73M	$15.16M	$7.300M	$15.15M	$3.830M	$13.11M	$10.98M	$8.990M	$14.74M	$5.390M	$1.340M	$7.040M
YoY Change	-25.1%	-49.67%	63.11%	107.67%	-51.82%	295.56%	-70.79%	19.4%	22.14%	-39.01%	173.47%	302.24%	-80.97%
Property, Plant & Equipment	$39.00K	$344.0K	$416.0K	$560.0K	$720.0K	$170.0K	$250.0K	$110.0K	$160.0K	$180.0K	$180.0K	$200.0K	$360.0K	$420.0K
YoY Change	-88.66%	-17.31%	-25.71%	-22.22%	323.53%	-32.0%	127.27%	-31.25%	-11.11%	0.0%	-10.0%	-44.44%	-14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.000K	$24.00K	$27.00K	$20.00K	$20.00K	$0.00	$20.00K	$30.00K	$20.00K	$20.00K	$20.00K	$0.00	$0.00	$20.00K
YoY Change	-87.5%	-11.11%	35.0%	0.0%		-100.0%	-33.33%	50.0%	0.0%	0.0%			-100.0%
Total Long-Term Assets	$42.00K	$368.0K	$443.0K	$580.0K	$740.0K	$170.0K	$270.0K	$290.0K	$180.0K	$200.0K	$200.0K	$200.0K	$350.0K	$440.0K
YoY Change	-88.59%	-16.93%	-23.62%	-21.62%	335.29%	-37.04%	-6.9%	61.11%	-10.0%	0.0%	0.0%	-42.86%	-20.45%
Total Assets	$9.364M	$12.81M	$25.17M	$15.74M	$8.040M	$15.32M	$4.100M	$13.40M	$11.16M	$9.190M	$14.94M	$5.590M	$1.690M	$7.480M
YoY Change
Accounts Payable	$657.0K	$779.0K	$283.0K	$730.0K	$810.0K	$550.0K	$510.0K	$920.0K	$1.160M	$290.0K	$160.0K	$420.0K	$390.0K	$720.0K
YoY Change	-15.66%	175.27%	-61.23%	-9.88%	47.27%	7.84%	-44.57%	-20.69%	300.0%	81.25%	-61.9%	7.69%	-45.83%
Accrued Expenses	$977.0K	$1.160M	$2.785M	$1.470M	$1.070M	$1.190M	$1.750M	$1.630M	$1.110M	$1.000M	$1.800M	$770.0K	$540.0K	$1.110M
YoY Change	-15.78%	-58.35%	89.46%	37.38%	-10.08%	-32.0%	7.36%	46.85%	11.0%	-44.44%	133.77%	42.59%	-51.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$3.140M
YoY Change													-100.0%
Long-Term Debt Due											$0.00	$10.00K	$30.00K	$50.00K
YoY Change											-100.0%	-66.67%	-40.0%
Total Short-Term Liabilities	$1.634M	$1.939M	$3.068M	$2.200M	$1.880M	$1.740M	$2.270M	$2.540M	$2.270M	$1.330M	$2.080M	$1.680M	$1.780M	$5.030M
YoY Change	-15.73%	-36.8%	39.45%	17.02%	8.05%	-23.35%	-10.63%	11.89%	70.68%	-36.06%	23.81%	-5.62%	-64.61%
Long-Term Debt	$0.00	$0.00	$0.00	$230.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$510.0K	$20.00K
YoY Change			-100.0%									-100.0%	2450.0%
Other Long-Term Liabilities	$0.00	$34.89K	$170.0K	$300.0K	$410.0K						$0.00	$30.00K	$0.00
YoY Change	-100.0%	-79.48%	-43.33%	-26.83%							-100.0%
Total Long-Term Liabilities	$0.00	$34.89K	$170.0K	$530.0K	$410.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$30.00K	$510.0K	$20.00K
YoY Change	-100.0%	-79.48%	-67.92%	29.27%							-100.0%	-94.12%	2450.0%
Total Liabilities	$1.634M	$1.974M	$3.238M	$2.720M	$2.290M	$1.740M	$2.270M	$2.540M	$2.270M	$1.330M	$2.080M	$1.710M	$2.280M	$5.050M
YoY Change	-17.22%	-39.04%	19.04%	18.78%	31.61%	-23.35%	-10.63%	11.89%	70.68%	-36.06%	21.64%	-25.0%	-54.85%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	2.084M shares	1.137M shares	1.069M shares
Diluted Shares Outstanding	2.084M shares	1.137M shares	1.069M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $1.9194 Million

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Marlborough, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2012-05-10. Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The firm's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The company is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The firm's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Industry: Pharmaceutical Preparations Peers: Benitec Biopharma Inc Cibus Inc Sonnet Biotherapeutics Holdings Inc Statera Biopharma Inc CohBar Inc Ensysce Biosciences Inc Exicure Inc Xenetic Biosciences Inc Navidea Biopharmaceuticals Inc